Rheumatoid arthritis: An evolutionary force in biologics

Current Pharmaceutical Design

Volumn 21, Issue 17, 2015, Pages 2170-2178

  Brown, Philip M ^a   Isaacs, John D ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Biologic; Biosimilar; DMARD; Immunogenicity; Rheumatoid arthritis; Translational medicine

Indexed keywords

BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; CYTOKINE INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; PROTEIN INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; RITUXIMAB;

ARTICLE; B LYMPHOCYTE; BIOLOGICAL THERAPY; CANCER RISK; CARDIOVASCULAR RISK; CELL THERAPY; DRUG COST; DRUG SAFETY; HUMAN; IMMUNOGENICITY; INFECTION RISK; LONG TERM CARE; LUNG FIBROSIS; MULTIPLE SCLEROSIS; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS; REMISSION; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; T LYMPHOCYTE; THERAPY EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VASCULITIS; ANIMAL; ARTHRITIS, RHEUMATOID;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; RITUXIMAB;

EID: 84929460544     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150310141827     Document Type: Article

References (75)

1. Waldmann H, Adams E, Cobbold S. Reprogramming the immune system: co-receptor blockade as a paradigm for harnessing tolerance mechanisms. Immunological Rev 2008; 223: 361-70.
2. Isaacs JD. Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future. Rheumatology 2008; 47(10): 1461-8.
3. Strand V, Kimberly R, Isaacs JD. Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov 2007; 6(1): 75-92.
4. Isaacs JD. From bench to bedside: discovering rules for antibody design, and improving serotherapy with monoclonal antibodies. Rheumatology (Oxford) 2001; 40(7): 724-38.
5. Isaacs JD. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists. Exp Opinion Biological Therapy 2009; 9(12): 1463-75.
6. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Eng J Med 2006; 355(10): 1018-28.
7. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003; 423(6937): 356-61.
8. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annl Rev Immunol 2001; 19: 163-96.
9. Thalayasingam N, Isaacs JD. Anti-TNF therapy. Best Practice Res 2011; 25(4): 549-67.
10. Moots RJ, Ostor AJ, Isaacs JD. Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the 'age of remission'? Exp Opinion Investigational Drugs 2009; 18(11): 1687-99.
11. Isaacs JD, Harari O, Kobold U, Lee JS, Bernasconi C. Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis. Arthritis Res Therapy 2013; 15(6): R204.
12. Protheroe A, Edwards JC, Simmons A, Maclennan K, Selby P. Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma. Rheumatology 1999; 38(11): 1150-2.
13. Wijbrandts CA, Dijkgraaf MG, Kraan MC, et al. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium. Annl Rheumatic Diseases 2008; 67(8): 1139-44.
14. van Vollenhoven RF, Kinnman N, Vincent E, Wax S, Bathon J. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebocontrolled trial. Arthritis Rheumatism 2011; 63(7): 1782-92.
15. Dorner T, Radbruch A, Burmester GR. B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol 2009; 5(8): 433-41.
16. Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004; 200(3): 277-85.
17. van den Berg WB, Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol 2009; 5(10): 549-53.
18. Patel DD, Lee DM, Kolbinger F, Antoni C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Annl Rheumatic Diseases 2013; Suppl 2: ii116-23.
19. Isaacs JD. The changing face of rheumatoid arthritis: sustained remission for all? Nat Rev Immunol 2010; 10(8): 605-11.
20. Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 2011; 50(1): 124-31.
21. Zink A, Manger B, Kaufmann J, et al. Evaluation of the RABBIT Risk Score for serious infections. Annl Rheumatic Diseases 2013.
22. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Systematic Rev 2011(2): CD008794.
23. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Eng J Med 2001; 345(15): 1098-104.
24. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Annals Rheumatic Diseases 2010; 69(3): 522-8.
25. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheumatism 2009; 60(7): 1884-94.
26. Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheumatism 2006; 54(8): 2368-76.
27. Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Annals RAheumatic Diseases 2011; 70(11): 1914-20.
28. Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annl Rev Med 2010; 61: 35-47.
29. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113(20): 4834-40.
30. Ray M, Curtis JR, Baddley JW. A case report of progressive multifocal leucoencephalopathy (PML) associated with adalimumab. Annl Rheumatic Diseases 2014; 73(7): 1429-30.
31. van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Annals Rheumatic Diseases 2013; 72(9): 1496-502.
32. Szlosarek PW, Balkwill FR. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol 2003; 4(9): 565-73.
33. Strangfeld A, Hyrich K, Askling J, et al. Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers. Rheumatology 2011; 50(1): 146-51.
34. Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and metaanalysis. Annl Rheumatic Diseases 2011; 70(11): 1895-904.
35. Mercer LK, Green AC, Galloway JB, et al. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Annl Rheumatic Diseases 2012; 71(6): 869-74.
36. Dixon WG, Watson KD, Lunt M, et al. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res 2010; 62(6): 755-63.
37. Seror R, Richez C, Sordet C, et al. Pattern of demyelination occurring during anti-TNF-alpha therapy: a French national survey. Rheumatology 2013; 52(5): 868-74.
38. Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs : Clin Immunotherapeutics, Biopharmaceuticals Gene Therapy 2002; 16(3): 183-200.
39. Guerra I, Algaba A, Perez-Calle JL, et al. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. J Crohn's Colitis 2012; 6(5): 518-23.
40. Jarrett SJ, Cunnane G, Conaghan PG, et al. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol 2003; 30(10): 2287-91.
41. Williams VL, Cohen PR. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol 2011; 50(5): 619-25.
42. Schoe A, van der Laan-Baalbergen NE, Huizinga TW, Breedveld FC, van Laar JM. Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab. Arthritis Rheumatism 2006; 55(1): 157-9.
43. Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Seminars arthritis Rheumatism 2010; 40(3): 233-40.
44. Giles JT, Fernandes V, Lima JA, Bathon JM. Myocardial dysfunction in rheumatoid arthritis: epidemiology and pathogenesis. Arthritis Res Therapy 2005; 7(5): 195-207.
45. Khanna D, McMahon M, Furst DE. Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here? Arthritis Rheumatism 2004; 50(4): 1040-50.
46. Listing J, Strangfeld A, Kekow J, et al. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheumatism 2008; 58(3): 667-77.
47. Westlake SL, Colebatch AN, Baird J, et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology 2011; 50(3): 518-31.
48. Listing J, Kekow J, Manger B, et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFalpha inhibitors and rituximab. Annals Rheumatic Diseases 2013.
49. Choy E, Sattar N. Interpreting lipid levels in the context of highgrade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Annl Rheumatic Diseases 2009; 68(4): 460-9.
50. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Annals Rheumatic Diseases 2013.
51. Singh JA, Furst DE, Bharat A, et al 2012 update of the 20American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012; 64(5): 625-39.
52. Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACTRAY). Annl Rheumatic Diseases 2013; 72(1): 43-50.
53. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA: the journal of the American Medical Association 2011; 305(14): 1460-8.
54. Vincent FB, Morand EF, Murphy K, et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Annl Rheumatic Diseases 2013; 72(2): 165-78.
55. Krieckaert CL, Bartelds GM, Lems WF, et al. The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Therapy 2010; 12(5): 217.
56. Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Annl Rheumatic Diseases 2012; 71(11): 1914-5.
57. Isaacs JD, Ferraccioli G. The need for personalised medicine for rheumatoid arthritis. Annl Rheumatic Diseases 2011; 70(1): 4-7.
58. Emery P, Dorner T. Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response. Annl Rheumatic Diseases 2011; 70(12): 2063-70.
59. Cui J, Stahl EA, Saevarsdottir S, et al. Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genetics 2013; 9(3): e1003394.
60. Jamnitski A, Bartelds GM, Nurmohamed MT, et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Annl Rheumatic Diseases 2011; 70(2): 284-8.
61. Garces S, Antunes M, Benito-Garcia E, et al. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. Annl Rheumatic Diseases 2013.
62. Pouw MF, Krieckaert CL, Nurmohamed MT, et al. Key findings towards optimising adalimumab treatment: the concentration-effect curve. Annl Rheumatic Diseases 2013.
63. Yoshida K, Sung YK, Kavanaugh A, et al. Biologic discontinuation studies: a systematic review of methods. Annl Rheumatic Diseases 2013.
64. Navarro-Millan I, Sattui SE, Curtis JR. Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis. Clin Therapeutics 2013; 35(11): 1850-61 e1.
65. Tanaka Y, Hirata S, Kubo S, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Annl Rheumatic Diseases 2013.
66. van den Broek M, Lems WF, Allaart CF. Do we need guidelines to stop as well as to start biological therapies for rheumatoid arthritis? Clin Exp Rheumatol 2012; 30(Suppl 73): S21-6.
67. van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recentonset rheumatoid arthritis. Annl Rheumatic Diseases 2009; 68(6): 914-21.
68. O'Dell JR, Curtis JR, Mikuls TR, et al. Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, doubleblind trial. Arthritis Rheumatism 2013; 65(8): 1985-94.
69. Smolen JS, Emery P, Fleischmann R, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet 2014; 383(9914): 321-32.
70. Nam JL, Villeneuve E, Hensor EM, et al. A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial. Annl Rheumatic Diseases 2014; 73(6): 1027-36.
71. Scheinberg MA, Kay J. The advent of biosimilar therapies in rheumatology--" O brave new world". Nat Rev Rheumatol 2012; 8(7): 430-6.
72. Kozlowski S, Woodcock J, Midthun K, Sherman RB. Developing the nation's biosimilars program. N Eng J Med 2011; 365(5): 385-8.
73. Dorner T, Strand V, Castaneda-Hernandez G, et al. The role of biosimilars in the treatment of rheumatic diseases. Annl Rheumatic Diseases 2013; 72(3): 322-8.
74. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Annl Rheumatic Diseases 2013; 72(10): 1605-12.
75. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Annl Rheumatic Diseases 2013; 72(10): 1613-20.